Share Price and Basic Stock Data
Last Updated: November 19, 2025, 11:34 pm
| PEG Ratio | 101.80 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Biogen Pharmachem Industries Ltd operates within the finance and investments sector, with a current share price of ₹0.77 and a market capitalization of ₹69.5 Cr. The company has experienced fluctuating revenue trends over recent quarters. In the June 2023 quarter, sales reported at ₹0.75, a notable recovery from previous quarters where sales were negative, such as in June 2022 (-₹1.54) and the September 2022 quarter (₹0.00). The company’s annual sales figures also illustrate volatility, with revenues standing at ₹2.38 Cr for the fiscal year ending March 2024, compared to ₹0.00 in March 2023. This indicates a potential rebound in operations, although the trailing twelve-month (TTM) sales figure of ₹1.58 Cr suggests that the company is still in the recovery phase. Overall, while there is a positive trend in recent quarters, the historical performance indicates significant challenges in maintaining consistent revenue generation.
Profitability and Efficiency Metrics
Biogen Pharmachem Industries Ltd’s profitability metrics reveal a complex financial landscape. The operating profit margin (OPM) rose to 87.01% in June 2025, reflecting strong cost management despite revenue fluctuations. However, the company has faced challenges in achieving consistent profitability, as evidenced by its operating profit of ₹1.34 Cr for the June 2025 quarter, following a loss of ₹0.16 Cr in the June 2024 quarter. The net profit for the latest reported quarter stood at ₹1.72 Cr, showcasing an improvement from previous losses in quarters like March 2023 (-₹0.20). The return on equity (ROE) and return on capital employed (ROCE) both stood at 0.39%, indicating a struggle to generate returns on shareholder investments effectively. This juxtaposition of high margins against inconsistent profitability underscores the need for sustained revenue growth to leverage operational efficiencies further.
Balance Sheet Strength and Financial Ratios
The balance sheet of Biogen Pharmachem Industries Ltd exhibits a unique financial structure, with no reported borrowings, a significant strength in today’s market. The company shows a current ratio of 29.65, suggesting a robust liquidity position, well above the typical sector average, which usually hovers around 1.5 to 2.0. The price-to-book value ratio is low at 0.68x, indicating that the stock might be undervalued relative to its net assets. The interest coverage ratio stands at 0.00x, which implies that the company does not have any interest obligations to cover, reflecting a debt-free status. However, the enterprise value has decreased to ₹60.63 Cr, down from ₹91.28 Cr in March 2022, raising questions about the company’s market perception and future growth potential. These financial ratios illustrate a company that is currently managing its liabilities effectively but may need to enhance its asset utilization to improve overall profitability.
Shareholding Pattern and Investor Confidence
Biogen Pharmachem Industries Ltd has a completely public shareholding pattern, with 100% of its equity held by the public as of March 2025. The number of shareholders has shown a steady increase, reaching 2,93,327, up from 1,90,531 in December 2022. This growth in shareholders may indicate rising interest and confidence in the company’s operations, particularly following its recent financial recovery. However, the absence of promoter or institutional investor holdings raises concerns about the lack of strategic backing that could drive further growth and stability. Investor sentiment appears cautiously optimistic, as reflected in the share price of ₹0.77, which is significantly lower than the book value of ₹1.41 per share as of March 2025. This disparity suggests that while there is interest, investors remain wary of the company’s historical volatility and future prospects.
Outlook, Risks, and Final Insight
Looking ahead, Biogen Pharmachem Industries Ltd holds potential opportunities for growth, particularly if it can sustain its recent revenue recovery. The positive trend in operating profit margins and the high liquidity position provide a foundation for future investments. However, risks remain, including the company’s historical volatility in earnings and the lack of institutional support, which could hinder its ability to capitalize on growth opportunities. Furthermore, maintaining operational efficiency amidst fluctuating sales will be crucial. Should the company successfully stabilize its revenue streams and enhance shareholder value, it could attract institutional investors, thereby improving market confidence. Conversely, failure to achieve consistent profitability may result in continued market skepticism and hinder its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biogen Pharmachem Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Monarch Networth Capital Ltd | 2,521 Cr. | 317 | 484/280 | 16.2 | 111 | 0.32 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 35.9 Cr. | 0.51 | 2.42/0.46 | 4.97 | 0.03 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.14 Cr. | 8.37 | 12.6/8.25 | 9.25 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 27.0 Cr. | 52.5 | 72.0/47.6 | 19.9 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Naperol Investments Ltd | 502 Cr. | 874 | 1,490/772 | 52.2 | 2,055 | 1.03 % | 1.06 % | 0.95 % | 10.0 |
| Industry Average | 7,004.09 Cr | 1,440.79 | 76.16 | 3,872.10 | 0.34% | 21.83% | 14.30% | 7.26 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -1.54 | -0.00 | -0.00 | -0.01 | 0.75 | -0.00 | -0.00 | 0.78 | -0.09 | -0.00 | 0.23 | 1.35 | 1.54 |
| Expenses | 0.05 | 0.11 | 0.03 | 0.19 | 0.34 | 0.04 | 0.03 | 0.04 | 0.07 | 0.35 | 0.54 | 0.17 | 0.20 |
| Operating Profit | -1.59 | -0.11 | -0.03 | -0.20 | 0.41 | -0.04 | -0.03 | 0.74 | -0.16 | -0.35 | -0.31 | 1.18 | 1.34 |
| OPM % | 54.67% | 94.87% | -134.78% | 87.41% | 87.01% | ||||||||
| Other Income | -0.00 | 2.05 | 0.33 | -0.00 | -0.00 | 0.76 | 0.09 | -0.00 | -0.00 | -0.65 | -0.00 | -0.00 | -0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| EPS in Rs | -0.02 | 0.03 | 0.00 | -0.00 | 0.01 | 0.01 | 0.00 | 0.01 | -0.00 | -0.02 | -0.00 | 0.02 | 0.01 |
Last Updated: August 1, 2025, 6:10 am
Below is a detailed analysis of the quarterly data for Biogen Pharmachem Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.54 Cr.. The value appears strong and on an upward trend. It has increased from 1.35 Cr. (Mar 2025) to 1.54 Cr., marking an increase of 0.19 Cr..
- For Expenses, as of Jun 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Mar 2025) to 0.20 Cr., marking an increase of 0.03 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For OPM %, as of Jun 2025, the value is 87.01%. The value appears to be declining and may need further review. It has decreased from 87.41% (Mar 2025) to 87.01%, marking a decrease of 0.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.02 (Mar 2025) to 0.01, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 2.38 | 1.20 | 1.58 |
| Expenses | 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.30 |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 0.28 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 17.72% | ||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 0.00 | 0.00 | 1.44 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 76.92% | -300.00% | -5366.67% | 100.00% | -1233.33% | 99.38% | 4700.00% | 319.57% | -115.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.92% | -376.92% | -5066.67% | 5466.67% | -1333.33% | 1332.71% | 4600.62% | -4380.43% | -434.59% |
Biogen Pharmachem Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| TTM: | 352% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 30% |
| 3 Years: | -2% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:41 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | ||||||
| ROCE % | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Diluted EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Cash EPS (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| PBDIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Net Profit / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Return on Networth / Equity (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return on Capital Employeed (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return On Assets (%) | -0.31 | 3.39 | 0.83 | -0.01 | -2.95 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Current Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Quick Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Enterprise Value (Cr.) | 60.63 | 69.16 | 38.37 | 91.28 | 13.70 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.89 | 8.44 |
| EV / EBITDA (X) | -207.15 | 35.82 | 84.25 | -10849.12 | -8.54 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.93 | 8.45 |
| Price / BV (X) | 0.68 | 1.22 | 0.70 | 1.69 | 0.25 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.94 | 8.47 |
| EarningsYield | 0.00 | 0.02 | 0.01 | 0.00 | -0.11 |
After reviewing the key financial ratios for Biogen Pharmachem Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 15. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 10. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return On Assets (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 5. It has decreased from 3.39 (Mar 24) to -0.31, marking a decrease of 3.70.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 3. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Quick Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 2. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60.63. It has decreased from 69.16 (Mar 24) to 60.63, marking a decrease of 8.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -207.15. This value is below the healthy minimum of 5. It has decreased from 35.82 (Mar 24) to -207.15, marking a decrease of 242.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.68, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biogen Pharmachem Industries Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.31% (Industry Average ROCE: 21.83%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.31% (Industry Average ROE: 14.3%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.4 (Industry average Stock P/E: 76.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | Shop No. 8, First Floor, Makers - 1 Building, Rajkot Gujarat 360001 | suntechnooverseas@gmail.com http://www.biogenpharma.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kelash Bunkar | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Aman Patel | Director |
| Mr. Harshadkumar Rathod | Director |